Saccharomyces boulardii and Reduced Diarrhea

Doses used in studies

mg/day: 1,000 (median 1,000, IQR 1,000–1,000) — 2 studies

Time to effect

Median: 3.2 weeks · IQR 2.3 weeks–4.1 weeks · Range 10 days–5 weeks — Reported in 2 of 2 studies

Safety in these studies

adverse events (overall)No significant difference
S. boulardii reduced the frequency of adverse events ( P = 0.033) in 14-day regimen, particularly treatment-associated diarrhea ( P = 0.032). However, after the adjustment to control Type I error, results lost their significance.
from: Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and
diarrheaNo significant difference
S. boulardii reduced the frequency of adverse events ( P = 0.033) in 14-day regimen, particularly treatment-associated diarrhea ( P = 0.032). However, after the adjustment to control Type I error, results lost their significance.
from: Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and

2 of 2 papersPopulation:

[Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].
- 2025-08-28
- RCT · n = 108
- Terapevticheskii arkhiv 97(8)
- - I V Maev
  - D N Andreev
  - R I Shaburov
  - A V Zaborovsky
  - A K Fomenko
  - P S Sokolov
  - S V Tsaregorodtsev
  - M K Devkota
  - D T Dicheva
  - S V Cheremushkin
  - N V Cheremushkinа
  - A V Vychkin
- PubMed: 40884341
- DOI: 10.26442/00403660.2025.08.203301
7 Insights on
- Reduced Diarrhea
- High evidence
- Large Human Trial
- Clinical
Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
500 mg twice daily
Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.
- 2023-11-06
- RCT · n = 404
- European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 33(3)
- - Olga Sjomina
  - Inese Poļaka
  - Jekaterina Suhorukova
  - Reinis Vangravs
  - Sergejs Paršutins
  - Viktoria Knaze
  - Jin Young Park
  - Rolando Herrero
  - Raul Murillo
  - Mārcis Leja
- PubMed: 37942999
- DOI: 10.1097/cej.0000000000000858
2 Insights on
- Reduced Diarrhea
- High evidence
- Large Human Trial
- Adults
S. boulardii reduced the frequency of adverse events (P = 0.033) in 14-day regimen, particularly treatment-associated diarrhea (P = 0.032). However, after the adjustment to control Type I error, results lost their significance.
Effect
Neutral
Effect size
Small
Significant
No
Dose
500 mg BID

Saccharomyces boulardii and Reduced Diarrhea

[Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].

Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.